CBClaudine Blin-Wakkach

Claudine Blin-Wakkach

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Claudine Blin-Wakkach has a total of 194 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Moesin controls cell–cell fusion and osteoclast function

    by Ophélie Dufrançais, Marianna Plozza, Marie Juzans, Arnaud Métais, Sarah C. Monard, Pierre-Jean Bordignon, Perrine Verdys, Thibaut Sanchez, Martin Bergert, Julia Halper, et al.

    Cell–cell fusion is an evolutionarily conserved process that is essential for many functions, including the formation of bone-resorbing multinucleated osteoclasts. Osteoclast multinucleation involves dynamic interactions between the actin cytoskeleton and the plasma membrane that are still poorly characterized. We found that moesin, a cytoskeletal linker protein member of the Ezrin, radixin, and moesin (ERM) protein family, plays a critical role in both osteoclast fusion and function. Moesin inhibition favors osteoclast multinucleation as well as HIV-1- and inflammation-induced cell fusion. Accordingly, moesin depletion decreases membrane-to-cortex attachment and enhances the formation of tunneling nanotubes, F-actin–based intercellular bridges triggering cell–cell fusion. In addition, moesin regulates the formation of the sealing zone, a key structure determining osteoclast bone resorption area, and thus controls bone degradation via a β3-integrin/RhoA/SLK pathway. Finally, moesin-deficient mice have reduced bone density and increased osteoclast abundance and activity. These findings provide a better understanding of cell–cell fusion and osteoclast biology, opening new opportunities to specifically target osteoclasts in bone disease therapy.


  • Open Access

    Macrophages and osteoclasts: similarity and divergence between bone phagocytes

    by Julia Halper, Bastien Dolfi, Stoyan Ivanov, Maria-Bernadette Madel, Claudine Blin-Wakkach

    Both macrophages and osteoclasts are vital immune components of the bone microenvironment. While macrophages play an essential role in phagocytosis, pathogen clearance and tissue remodeling, osteoclasts are well described for their bone resorption capacity. However, osteoclasts are much more than bone resorbing cells. While macrophages have been intensively studied as immune cells, the immune function of osteoclasts has long been neglected until recent evidence demonstrated that they play an important role in modulating immune responses. Both macrophages and osteoclasts exhibit the phenotypic and functional characteristic plasticity of the myeloid lineage, which depends on their origin and environment. Besides their common progenitors, osteoclasts and macrophages share several joint mechanisms ranging from cell fusion and phagocytosis to immune function and tissue remodeling. In this review, we discuss and illustrate the functional and characteristic parallels between macrophages and osteoclasts.


  • Open Access

    Dysregulated myeloid differentiation in colitis is induced by inflammatory osteoclasts in a TNFα-dependent manner

    by Maria-Bernadette Madel, Lidia Ibáñez, Thomas Ciucci, Julia Halper, Antoine Boutin, Ghada Beldi, Alice C. Lavanant, Henri-Jean Garchon, Matthieu Rouleau, Christopher G. Mueller, et al.


  • Open Access

    Interleukin-34 orchestrates bone formation through its binding to Bone Morphogenic Proteins

    by Dominique Heymann, Frédéric Lézot, Javier Munoz-Garcia, Jorge Vargas-Franco, Kristina Schiavone, Marcus T. Keatinge, Robin Young, Jérôme Amiaud, Laurie Fradet, Jean-François Jégou, et al.

    During growth, the contribution of IL34, a ligand of MCSFR, have not been established. The aim of this work was therefore to establish these implications using two models of IL34 invalidation generated in zebrafish and mouse. Significant growth delay and hypo-mineralization of skeletal elements were observed in both models, as well as craniofacial dysmorphoses in mice. With regard to bone cells, an unexpected increase in the number of osteoclasts and an accumulation of pre-osteoblasts were observed. In vitro analyses complemented by protein binding and molecular docking studies established that IL34 interacts directly with certain Bone Morphogenetic Proteins, modulating their various activities such as the stimulation of osteoblast differentiation. A new mechanism of action for IL34 has thus been characterized, opening up new therapeutic perspectives.

  • Open Access

    Moesin controls cell-cell fusion and osteoclast function

    by Ophélie Dufrancais, Perrine Verdys, Marianna Plozza, Arnaud Métais, Marie Juzans, Thibaut Sanchez, Martin Bergert, Julia Halper, Christopher J Panebianco, Rémi Mascarau, et al.

    Cell-cell fusion is an evolutionarily conserved process that is essential for many functions, including fertilisation and the formation of placenta, muscle and osteoclasts, multinucleated cells that are unique in their ability to resorb bone. The mechanisms of osteoclast multinucleation involve dynamic interactions between the actin cytoskeleton and the plasma membrane that are still poorly characterized. Here, we found that moesin, a cytoskeletal linker protein member of the Ezrin/Radixin/Moesin (ERM) protein family, is activated during osteoclast maturation and plays an instrumental role in both osteoclast fusion and function. In mouse and human osteoclast precursors, moesin inhibition favors their ability to fuse into multinucleated osteoclasts. Accordingly, we demonstrated that moesin depletion decreases membrane-to-cortex attachment and enhances the formation of tunneling nanotubes (TNTs), F-actin-based intercellular bridges that we reveal here to trigger cell-cell fusion. Moesin also controls HIV-1- and inflammation-induced cell fusion. In addition, moesin regulates the formation of the sealing zone, the adhesive structure determining osteoclast bone resorption area, and thus controls bone degradation, via a β3-integrin/RhoA/SLK pathway. Supporting our results, moesin - deficient mice present a reduced density of trabecular bones and increased osteoclast abundance and activity. These findings provide a better understanding of the regulation of cell-cell fusion and osteoclast biology, opening new opportunities to specifically target osteoclast activity in bone disease therapy.


  • Open Access

    New Insights into the Pro-Inflammatory and Osteoclastogenic Profile of Circulating Monocytes in Osteoarthritis Patients

    by Paloma Guillem-Llobat, Marta Marín, Matthieu Rouleau, Antonio Silvestre, Claudine Blin-Wakkach, María Luisa Ferrándiz, María Isabel Guillén, Lidia Ibáñez

    Osteoarthritis (OA) is a degenerative condition of the articular cartilage with chronic low-grade inflammation. Monocytes have a fundamental role in the progression of OA, given their implication in inflammatory responses and their capacity to differentiate into bone-resorbing osteoclasts (OCLs). This observational–experimental study attempted to better understand the molecular pathogenesis of OA through the examination of osteoclast progenitor (OCP) cells from both OA patients and healthy individuals (25 OA patients and healthy samples). The expression of osteoclastogenic and inflammatory genes was analyzed using RT-PCR. The OA monocytes expressed significantly higher levels of CD16, CD115, TLR2, Mincle, Dentin-1, and CCR2 mRNAs. Moreover, a flow cytometry analysis showed a significantly higher surface expression of the CD16 and CD115 receptors in OA vs. healthy monocytes, as well as a difference in the distribution of monocyte subsets. Additionally, the OA monocytes showed a greater osteoclast differentiation capacity and an enhanced response to an inflammatory stimulus. The results of this study demonstrate the existence of significant differences between the OCPs of OA patients and those of healthy subjects. These differences could contribute to a greater understanding of the molecular pathogenesis of OA and to the identification of new biomarkers and potential drug targets for OA.


  • Top Cited Papers
    Open Access

    New insights into inflammatory osteoclast precursors as therapeutic targets for rheumatoid arthritis and periodontitis

    by Emilie Hascoët, Frédéric Blanchard, Claudine Blin-Wakkach, Jérôme Guicheux, Philippe Lesclous, Alexandra Cloitre

    Rheumatoid arthritis (RA) and periodontitis are chronic inflammatory diseases leading to increased bone resorption. Preventing this inflammatory bone resorption is a major health challenge. Both diseases share immunopathogenic similarities and a common inflammatory environment. The autoimmune response or periodontal infection stimulates certain immune actors, leading in both cases to chronic inflammation that perpetuates bone resorption. Moreover, RA and periodontitis have a strong epidemiological association that could be explained by periodontal microbial dysbiosis. This dysbiosis is believed to be involved in the initiation of RA via three mechanisms. (i) The dissemination of periodontal pathogens triggers systemic inflammation. (ii) Periodontal pathogens can induce the generation of citrullinated neoepitopes, leading to the generation of anti-citrullinated peptide autoantibodies. (iii) Intracellular danger-associated molecular patterns accelerate local and systemic inflammation. Therefore, periodontal dysbiosis could promote or sustain bone resorption in distant inflamed joints. Interestingly, in inflammatory conditions, the existence of osteoclasts distinct from “classical osteoclasts” has recently been reported. They have proinflammatory origins and functions. Several populations of osteoclast precursors have been described in RA, such as classical monocytes, a dendritic cell subtype, and arthritis-associated osteoclastogenic macrophages. The aim of this review is to synthesize knowledge on osteoclasts and their precursors in inflammatory conditions, especially in RA and periodontitis. Special attention will be given to recent data related to RA that could be of potential value in periodontitis due to the immunopathogenic similarities between the two diseases. Improving our understanding of these pathogenic mechanisms should lead to the identification of new therapeutic targets involved in the pathological inflammatory bone resorption associated with these diseases.


  • Open Access

    WHIM Syndrome-linked CXCR4 mutations drive osteoporosis

    by Adrienne Anginot, Julie Nguyen, Zeina Abou Nader, Vincent Rondeau, Amélie Bonaud, Maria Kalogeraki, Antoine Boutin, Julia P. Lemos, Valeria Bisio, Joyce Koenen, et al.

    WHIM Syndrome is a rare immunodeficiency caused by gain-of-function CXCR4 mutations. Here we report a decrease in bone mineral density in 25% of WHIM patients and bone defects leading to osteoporosis in a WHIM mouse model. Imbalanced bone tissue is observed in mutant mice combining reduced osteoprogenitor cells and increased osteoclast numbers. Mechanistically, impaired CXCR4 desensitization disrupts cell cycle progression and osteogenic commitment of skeletal stromal/stem cells, while increasing their pro-osteoclastogenic capacities. Impaired osteogenic differentiation is evidenced in primary bone marrow stromal cells from WHIM patients. In mice, chronic treatment with the CXCR4 antagonist AMD3100 normalizes in vitro osteogenic fate of mutant skeletal stromal/stem cells and reverses in vivo the loss of skeletal cells, demonstrating that proper CXCR4 desensitization is required for the osteogenic specification of skeletal stromal/stem cells. Our study provides mechanistic insights into how CXCR4 signaling regulates the osteogenic fate of skeletal cells and the balance between bone formation and resorption.


  • Open Access

    Specific targeting of inflammatory osteoclastogenesis by the probiotic yeast S. boulardii CNCM I-745 reduces bone loss in osteoporosis

    by Maria-Bernadette Madel, Julia Halper, Lidia Ibáñez, Lozano Claire, Matthieu Rouleau, Antoine Boutin, Adrien Mahler, Rodolphe Pontier-Bres, Thomas Ciucci, Majlinda Topi, et al.

    Bone destruction is a hallmark of chronic inflammation, and bone-resorbing osteoclasts arising under such a condition differ from steady-state ones. However, osteoclast diversity remains poorly explored. Here, we combined transcriptomic profiling, differentiation assays and in vivo analysis in mouse to decipher specific traits for inflammatory and steady-state osteoclasts. We identified and validated the pattern-recognition receptors (PRR) Tlr2, Dectin-1, and Mincle, all involved in yeast recognition as major regulators of inflammatory osteoclasts. We showed that administration of the yeast probiotic Saccharomyces boulardii CNCM I-745 (Sb) in vivo reduced bone loss in ovariectomized but not sham mice by reducing inflammatory osteoclastogenesis. This beneficial impact of Sb is mediated by the regulation of the inflammatory environment required for the generation of inflammatory osteoclasts. We also showed that Sb derivatives as well as agonists of Tlr2, Dectin-1, and Mincle specifically inhibited directly the differentiation of inflammatory but not steady-state osteoclasts in vitro. These findings demonstrate a preferential use of the PRR-associated costimulatory differentiation pathway by inflammatory osteoclasts, thus enabling their specific inhibition, which opens new therapeutic perspectives for inflammatory bone loss.


  • Open Access

    Specific targeting of inflammatory osteoclastogenesis by the probiotic yeast S. boulardii CNCM I-745 reduces bone loss in osteoporosis

    by Maria-Bernadette Madel, Julia Halper, Lidia Ibáñez, Claire Lozano, Matthieu Rouleau, Antoine Boutin, Rodolphe Pontier-Bres, Thomas Ciucci, Majlinda Topi, Christophe Hue, et al.

    Bone destruction is a hallmark of chronic inflammation, and bone-resorbing osteoclasts arising under such a condition differ from steady-state ones. However, osteoclast diversity remains poorly explored. Here, we combined transcriptomic profiling, differentiation assays and in vivo analysis in mouse to decipher specific traits for inflammatory and steady state osteoclasts. We identified and validated the pattern-recognition receptors (PRR) TLR2, Dectin-1 and Mincle, all involved in yeast recognition as major regulators of inflammatory osteoclasts. We showed that administration of the yeast probiotic Saccharomyces boulardi CNCM I-745 ( Sb ) in vivo reduced bone loss in OVX but not sham mice by reducing inflammatory osteoclasts. This beneficial impact of Sb is mediated by the regulation of the inflammatory environment required for the generation of inflammatory osteoclasts. We also showed that Sb derivatives as well as agonists of TLR2, Dectin-1 and Mincle specifically inhibited directly the differentiation of inflammatory but not steady state osteoclasts in vitro . These findings demonstrate a preferential use of the PRR-associated costimulatory differentiation pathway by inflammatory osteoclasts, thus enabling their specific inhibition, which opens new therapeutic perspectives for inflammatory bone loss.